Cushing’s syndrome and COVID-19.

Publication date: Nov 14, 2024

This review aims to present current data on the course of COVID-19 in patients with Cushing syndrome (CS) and discuss treatment for CS during to the pandemic. Literature review using PubMed (pubmed. ncbi. nlm. nih. gov). The search included the following terms: “COVID19” in combination with “Cushing syndrome”, “Hypercortisolism” and “Glucocorticoid”. Chronic hypercortisolism has been reported to increase infectious risk and worsens prognostic of patients with COVID-19 potentially due to its direct impact on the immune system: lymphopenia, impairment of monocytes and neutrophils activity, diminution of complement activation. Main metabolic complications of CS – i. e. diabetes, hypertension and obesity – have been recognized as COVID-19 complications risk factors. Patients with CS treated with steroidogenesis inhibitors might experience adrenal insufficiency during COVID-19. Special attention should be paid to patients with CS and COVID-19. The pandemic has impacted – and delayed – care of chronic illnesses including CS. Specific recommendations had been provided during the pandemic: favor telemedicine consultations, limit in-hospital explorations and postpone surgery when feasible. There are enough evidence for an increased prevalence and severity of COVID-19 to recommend a specific attention and caution in patients with CS.

Concepts Keywords
Covid19 COVID-19
Diabetes Cushing disease
Pandemic Physiopathology
Steroidogenesis Risk factors
Surgery SARS-CoV-2

Semantics

Type Source Name
disease MESH Cushing’s syndrome
disease MESH COVID-19
pathway KEGG Cushing syndrome
pathway REACTOME Immune System
disease MESH lymphopenia
disease MESH complications
disease MESH hypertension
disease MESH obesity
disease MESH adrenal insufficiency
disease MESH chronic illnesses
disease MESH Long Covid
disease MESH Cushing disease

Original Article

(Visited 3 times, 1 visits today)